TABLE 1

Clinical Profile of Study Patients with IPF

Patient no.	Smoker	TLC^*	FEV₁	TL_CO	HRCT	Treated	Comorbidity	SUV_max
1	X	71	68	65	UIP	N	None	3.2
2	X	75	68	38	UIP	N	COPD	1.5
3	X	57	74	42	UIP	N	None	3.2
4	N	58	94	59	UIP	N	Cardiac	2
5	X	69	92	56	UIP	N	None	1.8
6	X	72	40	51	UIP	N	None	2.2
7	X	59	74	49	UIP	N	None	2
8	Y	60	84	49	UIP	N	None	2.2
9	N	43	50	29	UIP	N	None	2
10	X	70	80	59	UIP	N	None	2.9
11	X	—	78	—	UIP	N	None	5.4
12	X	50	71	35	UIP	N	None	4.4
13	N	—	48	—	UIP	N	None	4.9
14	X	—	97	62	UIP	N	COPD	1.9
15	N	89	89	42	UIP	N	None	2.4
16	X	70	76	51	UIP	N	None	2.8
17	N	73	75	75	UIP	N	Cardiac	1.9
18	X	63	26	34	UIP	N	None	3.6

↵* PFTs are percentage predicted.
X = ex-smoker; N = no; Y = yes; TLC = total lung capacity.
These patients had typical clinical and physiologic data of IPF, including exclusion of other causes of DLPD such as connective tissue disease, medication, radiotherapy, and dust exposures, and typical UIP appearances on HRCT were observed (1). Findings in 1 patient were not completely typical, and therefore, for clinical reasons, patient underwent biopsy, which showed UIP.